Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib-rituximab.

Authors :: Gentile M
Martino EA
Visentin A
Coscia M
Reda G
Sportoletti P
Mauro FR
Laurenti L
Varettoni M
Murru R
Chiarenza A
Vigna E
Mendicino F
Lucia E
Bossio S
Recchia AG
Moia R
Pietrasanta D
Loseto G
Consoli U
Scortechini I
Rossi FM
Zucchetto A
Al-Janazreh H
Vitale C
Tripepi G
D'Arrigo G
Angeletti I
Bomben R
Neri A
Cutrona G
Fronza G
Di Raimondo F
Gaidano G
Cuneo A
Foà R
Ferrarini M
Trentin L
Gattei V
Morabito F
Source :: Blood cancer journal [Blood Cancer J] 2020 Sep 16; Vol. 10 (9), pp. 92. Date of Electronic Publication: 2020 Sep 16.
Publication Year :: 2020

Subjects :: Adult
Aged
Aged, 80 and over
Disease-Free Survival
Female
Humans
Male
Middle Aged
Purines administration & dosage
Quinazolinones administration & dosage
Rituximab administration & dosage
Survival Rate
Antineoplastic Combined Chemotherapy Protocols administration & dosage
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell mortality

Full Text Access

Tools